Translate
Zenas Biopharma, Inc.
About
18.73USD-0.24 -1.27%
Closed • Updated at 06:04 GMT+00:00Market Cap$1.18B
Volume407.7K
Beta0.06
RSI46.16
Zenas Biopharma, Inc. — investor relations, events, news, and company updates on 6ix.
Latest News
May 13 2026
Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor
Mar 27 2026
Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million
Mar 26 2026
Zenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common Stock
Mar 16 2026
Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Feb 9 2026
Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026
Recent Videos
AMZ Trading Zenas BioPharma ZBIO Deep Dive 1080p caption 1
May 25, 2026
CEO Bought ZBIO | May 19, 2026 #Shorts
May 20, 2026
$2 Million of Insider Buying at Zenas BioPharma: The Real Signal
May 19, 2026
ZBIO: CEO just bought $617K | Apr 30, 2026 #Shorts
May 01, 2026
Community Chat
Ask AI
Try asking